comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists of semaglutide for patients type 2 diabetes in clinical practice The cardiovascular effects of GLP-1

However, as this analysis was conducted post hoc, the findings should be interpreted with caution and considered hypothesis-generating rather than evidence of superiority between agents

this complication does not appear to be a class-driven effect

AP events were predominantly reported for unknown indications (53.8%) and T2DM (43.0%)

Schwartz had strong expertise in peptide sequencing techniques that he had acquired while a postdoctoral researcher with Steiner at the University of Chicago

This dual action on both glycemic control and cardiovascular health has elevated GLP-1 receptor agonists to an important position in diabetes management